Monocyte-derived Dendritic Cells Generated After a Short-term Culture with IFN-alpha and Granulocyte-macrophage Colony-stimulating Factor Stimulate a Potent Epstein-Barr Virus-specific CD8+ T Cell Response
Overview
Authors
Affiliations
Cellular immune responses are crucial for the control of EBV-associated lymphoproliferative diseases. To induce an anti-EBV cell-mediated immunity, we have used dendritic cells (DCs) generated by a 3-day culture of human CD14(+) monocytes in the presence of GM-CSF and type I IFN (IFN-DCs) and pulsed with peptides corresponding to CTL EBV epitopes. The functional activity of IFN-DCs was compared with that of APCs differentiated by culturing monocytes for 3 days with GM-CSF and IL-4 and indicated as IL-4-DCs. Stimulation of PBLs from EBV-seropositive donors with EBV peptide-pulsed autologous IFN-DCs resulted in a stronger expansion of specific T lymphocytes producing IFN-gamma with respect to stimulation with peptide-loaded IL-4-DCs, as assessed by ELISPOT assays. When purified CD8(+) T cells were cocultured with EBV peptide-pulsed IFN-DCs or IL-4-DCs, significantly higher levels of specific cytotoxic activity were observed in CD8(+) T cell cultures stimulated with IFN-DCs. Injection of peptide-pulsed IFN-DCs into SCID mice transplanted with autologous PBLs led to the recovery of a significantly greater number of EBV-specific human CD8(+) T cells from the spleen and the peritoneal cavity with respect to that recovered from mice injected with peptide-pulsed IL-4-DCs. Moreover, a significant delay in lymphoma development was observed when peptide-pulsed IFN-DCs were injected into SCID mice reconstituted with PBMCs endowed with a high capability of lymphoma induction, whereas injection of unpulsed IFN-DCs was ineffective. Our results indicate that IFN-DCs efficiently promote in vitro and in vivo the expansion of CD8(+) T lymphocytes acting as cytotoxic effectors against EBV-transformed cells.
Kim H, Shin S, Park S, Park J, Kim S, Lee Y Front Immunol. 2025; 15:1491043.
PMID: 39742276 PMC: 11687127. DOI: 10.3389/fimmu.2024.1491043.
Sepahpour T, Alshaweesh J, Azodi N, Singh K, Ireland D, Valanezhad F NPJ Vaccines. 2024; 9(1):250.
PMID: 39702382 PMC: 11659581. DOI: 10.1038/s41541-024-01032-6.
Cao Z, Zhang K, Zhang H, Zhang H, Yu Y, Yin D Front Microbiol. 2022; 13:965997.
PMID: 35992660 PMC: 9382107. DOI: 10.3389/fmicb.2022.965997.
Korenfeld D, Roussak K, Dinkel S, Vogel T, Pollack H, Levy J J Immunol. 2021; 207(10):2423-2432.
PMID: 34654687 PMC: 8578438. DOI: 10.4049/jimmunol.2000841.
Mao C, Beiss V, Fields J, Steinmetz N, Fiering S Biomaterials. 2021; 275:120914.
PMID: 34126409 PMC: 8542346. DOI: 10.1016/j.biomaterials.2021.120914.